US20010039438A1 - Method for treating neovascularization - Google Patents
Method for treating neovascularization Download PDFInfo
- Publication number
- US20010039438A1 US20010039438A1 US09/814,572 US81457201A US2001039438A1 US 20010039438 A1 US20010039438 A1 US 20010039438A1 US 81457201 A US81457201 A US 81457201A US 2001039438 A1 US2001039438 A1 US 2001039438A1
- Authority
- US
- United States
- Prior art keywords
- agent
- angiogenic
- administration
- photosensitive agent
- photosensitive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N C1CC1 Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- AXEZKQNYVDNGPB-UHFFFAOYSA-N CC1=CC=C(NC(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)C=C1NC1=NC(C2=CN=CC=C2)=CC=N1.CC1=CC=C(NC(=O)C2=CC=CC=C2)C=C1NC1=NC=CC(C2=CC=CN=C2)=N1.ClC1=CC=C(N/C2=N/N=C(/CC3=CC=NC=C3)C3=CC=CC=C32)C=C1 Chemical compound CC1=CC=C(NC(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)C=C1NC1=NC(C2=CN=CC=C2)=CC=N1.CC1=CC=C(NC(=O)C2=CC=CC=C2)C=C1NC1=NC=CC(C2=CC=CN=C2)=N1.ClC1=CC=C(N/C2=N/N=C(/CC3=CC=NC=C3)C3=CC=CC=C32)C=C1 AXEZKQNYVDNGPB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Definitions
- the invention relates to an improved method to treat ocular neovascularization, such as subfoveal choroidal neovascularization (CNV) by use of an anti-angiogenic agent as an adjunct to photodynamic therapy (PDT).
- CNV subfoveal choroidal neovascularization
- PDT photodynamic therapy
- ASD age related macular degeneration
- PDT photodynamic therapy
- a treatment regimen which could be used in conjunction with PDT, and which would prevent the growth of new vessels, would be advantageous for the treatment of CNV.
- the prevention of new, unwanted neovasculature could reduce the number of PDT treatments required in some subjects.
- the methods of the invention can also be used to treat other types of ocular tissue afflicted with neovascularization, such as retinal neovascular lesions due to, e.g., diabetes.
- the present invention relates to a method for treating unwanted neovasculature in a subject, comprising:
- the invention in another aspect, relates to a kit comprising at least one anti-angiogenic agent and at least one photosensitive agent.
- PDT as a treatment is well known in the art, and generally involves the use of a photosensitive agent activated by a laser.
- Preferred methods and compositions for PDT treatment of neovascularization utilizing a photosensitive agent and laser treatment is disclosed in U.S. Pat. Nos. 4,920,143; 5,095,030; 5,214,036; 5,707,608; 6,074,666; 5,770,619; 5,798,349; 5,756,541; 4,883,790; and 5,283,255, all of which are expressly incorporated by reference herein in their entirety.
- the photosensitive agent lodges in the ocular tissue affected by neovascularization (i.e., the target ocular tissue) and is activated by a laser having a wavelength absorbable by the photosensitive agent.
- an anti-angiogenic agent is administered before, after and/or simultaneously with the photosensitive agent used in the PDT treatment.
- the combination of PDT and anti-angiogenic agent is referred to herein as “adjunctive PDT”.
- an anti-angiogenic agent may be administered between about 0 and about 4 weeks, more preferably between about 0.5 and about 1.5 weeks, before administration of the photosensitive agent.
- the anti-angiogenic agent may be administered between about 0 and about 4 weeks, more preferably between about 0 and about 1 week, after administration of the photosensitive agent.
- the anti-angiogenic agent may be sequentially administered both before and after PDT according to the schedule described above.
- the treatment is considered simultaneous if the anti-angiogenic is co-administered with the photosensitive agent.
- Particular subjects may require multiple adjunctive PDT treatments.
- Particular adjunctive PDT treatments may require multiple administrations of the anti-angiogenic agent before PDT, multiple administrations of anti-angiogenic agent after PDT, or both.
- Anti-angiogenic agents mean agents that work by preventing, inhibiting or reversing the growth of new blood vessels via the process commonly known as angiogenesis.
- anti-angiogenic agents useful in adjunctive PDT include staurosporins, for example N-benzoyl-staurosporine, somatostatins, such as octreotide
- VEGF inhibitors such as CGP 79987D, CGP 57 148B or CGP 53 716,
- anti-angiogenic agents are particularly useful to inhibit the recurrence, re-opening, development and I or progression of blood vessel growth that occurs during choroidal neovascularization, and offer significant benefits in adjunctive PDT.
- Preferred anti-angiogenic agents are inhibitors of protein kinase C (PKC) (e.g., N-benzoyl-staurosporine), antagonists of growth hormone and IGF-1 (e.g., octreotide), antagonists of vascular endothelial growth factor (VEGF) (e.g., CGP 79787, N-benzoyl-staurosporine, CAM 781), inhibitors of cyclooxygenase II (e.g., diclofenac, rofecoxib, celecoxib, and the like), antagonists of angiotensin II (e.g., valsartan), antagonists of NF-kappa B, and PLA2 antagonists. More preferred anti-angiogenic agents are PKC inhibitors, VEGF antagonists and antagonists of growth hormone and IGF-1.
- PKC protein kinase C
- VEGF vascular endothelial growth factor
- anti-angiogenic agents are inhibitors of PKC and antagonists of VEGF, in particular inhibitors of PKC, such as N-benzoyl-staurosporine, CGP 79787, and octreotide. Particularly preferred is N-benzoyl-staurosporine.
- Preferred photosensitive agents are the chlorins, bacteriochlorins, phthalocyanines, porphyrins, purpurins, merocyanines, pheophorbides and psoralens.
- porphyrins are the porphyrins and is most preferably the a green porphyrin, in particular benzoporphyrin derivative monoacid ring A (“BPD-MA”).
- BPD-MA benzoporphyrin derivative monoacid ring A
- photosensitive compounds described above can be used in the methods of the invention.
- mixtures of two or more photosensitive compounds can also be used; however, the effectiveness of the treatment depends on the absorption of light by the photosensitive compound so that if mixtures are used, components with similar absorption maxima are preferred.
- the nature of the formulation used to deliver the anti-angiogenic agent or photosensitive agent will depend in part on the mode of administration and on the nature of the anti-angiogenic agent and the photosensitive agent selected. Any pharmaceutically acceptable excipient, or combination thereof, appropriate to the particular active compounds may be used.
- the photosensitive agents or anti-angiogenic compounds may be administered as an aqueous composition, as a transmucosal or transdermal composition, as a subtenons or intraocular injection or in an oral formulation.
- the formulation may also include liposomes. Liposomal compositions are particularly preferred especially where the photosensitive agent is a green porphyrin.
- the anti-angiogenic agent is preferably administered via an aqueous carrier.
- anti-angiogenic agents can be administered in any of a wide variety of ways, for example, orally, parenterally, or rectally, or the compound may be placed directly in or on the eye.
- Parenteral administration such as intravenous, intramuscular, or subcutaneous, is preferred for the photosensitive agent. Intravenous injection is especially preferred.
- Oral administration or ocular administration is preferred for administration of the anti-angiogenic agent.
- the dose of the above compounds can vary widely depending upon the mode of administration; the formulation in which it is carried, such as in the form of liposomes, or whether it is coupled to a target-specific ligand, such as an antibody or an immunologically active fragment.
- a target-specific ligand such as an antibody or an immunologically active fragment.
- the anti-antigenic agent is administered in a manner and amount sufficient to effect agent interaction with the unwanted neovasculature.
- the photosensitive agent is administered in an amount effective to close or eradicate the unwanted neovasculature upon irradiation with light of the appropriate wavelength.
- a typical dosage is of the range of 0.1-50 mg/m 2 of body surface area, preferably from about 1-10 mg/m 2 and even more preferably about 2-8 mg/m 2 .
- a typical dosage is of the range of 1-500 mg/kg of body weight, preferably from about 10-250 mg/kg of body weight.
- the irradiation (laser power, irradiation duration) is carried out in accordance to methods known in the art as mentioned above, for example in accordance to the light treatment protocols set out in U.S. Pat. Nos. 5,770,619; 5,798,349; 5,756,541; 4,883,790; and 5,283,255.
- Kits that contain an anti-angiogenic agent and a photosensitive agent are also within the scope of the invention. Such kits can also contain suitable vehicles for the reconstitution or administration of the aforesaid anti-angiogenic agents as well as devices for the administration of such agents.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/814,572 US20010039438A1 (en) | 2000-03-24 | 2001-03-22 | Method for treating neovascularization |
US11/484,473 US20060263392A1 (en) | 2000-03-24 | 2006-07-11 | Method for treating neovascularization |
US11/975,325 US8158669B2 (en) | 2000-03-24 | 2007-10-18 | Method for treating neovascularization |
US13/448,242 US8862224B2 (en) | 2000-03-24 | 2012-04-16 | Method for treating neovascularization |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19180700P | 2000-03-24 | 2000-03-24 | |
US09/814,572 US20010039438A1 (en) | 2000-03-24 | 2001-03-22 | Method for treating neovascularization |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/484,473 Continuation US20060263392A1 (en) | 2000-03-24 | 2006-07-11 | Method for treating neovascularization |
Publications (1)
Publication Number | Publication Date |
---|---|
US20010039438A1 true US20010039438A1 (en) | 2001-11-08 |
Family
ID=22707008
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/814,572 Abandoned US20010039438A1 (en) | 2000-03-24 | 2001-03-22 | Method for treating neovascularization |
US11/484,473 Abandoned US20060263392A1 (en) | 2000-03-24 | 2006-07-11 | Method for treating neovascularization |
US11/975,325 Expired - Fee Related US8158669B2 (en) | 2000-03-24 | 2007-10-18 | Method for treating neovascularization |
US13/448,242 Expired - Fee Related US8862224B2 (en) | 2000-03-24 | 2012-04-16 | Method for treating neovascularization |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/484,473 Abandoned US20060263392A1 (en) | 2000-03-24 | 2006-07-11 | Method for treating neovascularization |
US11/975,325 Expired - Fee Related US8158669B2 (en) | 2000-03-24 | 2007-10-18 | Method for treating neovascularization |
US13/448,242 Expired - Fee Related US8862224B2 (en) | 2000-03-24 | 2012-04-16 | Method for treating neovascularization |
Country Status (21)
Country | Link |
---|---|
US (4) | US20010039438A1 (no) |
EP (1) | EP1265636A2 (no) |
JP (1) | JP2003528926A (no) |
KR (2) | KR20020082487A (no) |
CN (1) | CN100398153C (no) |
AR (1) | AR032151A1 (no) |
AU (2) | AU5040101A (no) |
BR (1) | BR0109499A (no) |
CA (1) | CA2403612A1 (no) |
CZ (1) | CZ20023174A3 (no) |
EE (1) | EE200200547A (no) |
HU (1) | HUP0300347A3 (no) |
IL (1) | IL151833A0 (no) |
MX (1) | MXPA02009351A (no) |
NO (1) | NO20024486D0 (no) |
NZ (1) | NZ521360A (no) |
PL (1) | PL359027A1 (no) |
RU (1) | RU2271222C2 (no) |
UA (1) | UA75350C2 (no) |
WO (1) | WO2001074389A2 (no) |
ZA (1) | ZA200207638B (no) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030171320A1 (en) * | 2001-11-09 | 2003-09-11 | Guyer David R. | Methods for treating ocular neovascular diseases |
US20040122491A1 (en) * | 2001-02-06 | 2004-06-24 | Strong H. Andrew | Reduced fluence rate PDT |
US20040243198A1 (en) * | 2002-10-03 | 2004-12-02 | Light Sciences Corporation | System and method for excitation of photoreactive compounds in eye tissue |
US20050043786A1 (en) * | 2003-08-18 | 2005-02-24 | Medtronic Ave, Inc. | Methods and apparatus for treatment of aneurysmal tissue |
US20050244500A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
US20100310542A1 (en) * | 2007-07-30 | 2010-12-09 | Healor Ltd. | Pharmaceutical Compositions for treating wouds and related methods |
US8367606B2 (en) | 2005-08-29 | 2013-02-05 | Healor Ltd. | Method and compositions for prevention and treatment of diabetic and aged skin |
US8507431B2 (en) | 2003-08-07 | 2013-08-13 | Healor Ltd. | Methods for accelerating wound healing by administration of a preadipocyte modulator or an adipocyte modulator |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ521360A (en) * | 2000-03-24 | 2004-07-30 | Novartis Ag | Improved treatment of neovascularization |
AU2002248284A1 (en) * | 2000-11-01 | 2002-08-06 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
GB0122318D0 (en) * | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
FR2867189A1 (fr) * | 2004-03-08 | 2005-09-09 | Ludovic Bourre | Nouveaux composes medicamenteux destines au traitement des pathologies dependantes de l'activite proteine kinase |
WO2006015016A2 (en) | 2004-07-30 | 2006-02-09 | Massachusetts Eye And Ear Infirmary | Photodynamic therapy and compositions for treating ocular glaucoma |
US8753673B2 (en) * | 2006-05-23 | 2014-06-17 | Taiwan Liposome Co. Ltd. | Liposome composition for delivery of a therapeutic agent to eyes |
GB0811955D0 (en) | 2008-06-30 | 2008-07-30 | Pci Biotech As | Method |
EP2156834A1 (en) * | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
ES2468827T3 (es) | 2010-01-14 | 2014-06-17 | Sanwa Kagaku Kenkyusho Co., Ltd | Producto farmacéutico para prevenir o tratar trastornos acompañados de angiog�nesis ocular y/o permeabilidad vascular ocular elevada |
RU2449821C1 (ru) * | 2010-09-01 | 2012-05-10 | Федеральное государственное бюджетное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "МНИОИ им. П.А.Герцена Минздравсоцразвития России") | Способ модификации фотодинамического лечения |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5770619A (en) * | 1992-11-20 | 1998-06-23 | University Of British Columbia | Method of activating photosensitive agents |
US6117862A (en) * | 1998-10-09 | 2000-09-12 | Qlt, Inc. | Model and method for angiogenesis inhibition |
US6214819B1 (en) * | 1998-11-23 | 2001-04-10 | Novartis Ag | Method for treating ocular neovascular diseases |
US6271233B1 (en) * | 1999-08-10 | 2001-08-07 | Ciba Vision Corporation | Method for treating ocular neovascular diseases |
US6297228B1 (en) * | 1991-11-22 | 2001-10-02 | Alcon Manufacturing, Ltd. | Use of angiostatic steroids in photodynamic therapy |
US20020040015A1 (en) * | 2000-02-10 | 2002-04-04 | Miller Joan W. | Methods and compositions for treating conditions of the eye |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4883790A (en) * | 1987-01-20 | 1989-11-28 | University Of British Columbia | Wavelength-specific cytotoxic agents |
US5283255A (en) * | 1987-01-20 | 1994-02-01 | The University Of British Columbia | Wavelength-specific cytotoxic agents |
US5095030A (en) * | 1987-01-20 | 1992-03-10 | University Of British Columbia | Wavelength-specific cytotoxic agents |
US4920143A (en) * | 1987-04-23 | 1990-04-24 | University Of British Columbia | Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents |
US5214036A (en) * | 1990-03-08 | 1993-05-25 | University Of British Columbia | Benzoporphyrin derivatives for photodynamic therapy |
CA2087902C (en) * | 1992-02-05 | 2006-10-17 | Narendra Raghunathji Desai | Liposome compositions of porphyrin photosensitizers |
US5798349A (en) * | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
US5707608A (en) * | 1995-08-02 | 1998-01-13 | Qlt Phototherapeutics, Inc. | Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer |
US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
PL349216A1 (en) * | 1998-12-23 | 2002-07-01 | Searle & Co | Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia |
AU2001227837A1 (en) * | 2000-01-12 | 2001-07-24 | Light Sciences Corporation | Novel treatment for eye disease |
NZ521360A (en) * | 2000-03-24 | 2004-07-30 | Novartis Ag | Improved treatment of neovascularization |
-
2001
- 2001-03-22 NZ NZ521360A patent/NZ521360A/en unknown
- 2001-03-22 MX MXPA02009351A patent/MXPA02009351A/es not_active Application Discontinuation
- 2001-03-22 HU HU0300347A patent/HUP0300347A3/hu unknown
- 2001-03-22 UA UA2002097520A patent/UA75350C2/uk unknown
- 2001-03-22 BR BR0109499-8A patent/BR0109499A/pt not_active Application Discontinuation
- 2001-03-22 CZ CZ20023174A patent/CZ20023174A3/cs unknown
- 2001-03-22 PL PL01359027A patent/PL359027A1/xx unknown
- 2001-03-22 AR ARP010101344A patent/AR032151A1/es unknown
- 2001-03-22 AU AU5040101A patent/AU5040101A/xx active Pending
- 2001-03-22 WO PCT/EP2001/003265 patent/WO2001074389A2/en active IP Right Grant
- 2001-03-22 CN CNB018071449A patent/CN100398153C/zh not_active Expired - Fee Related
- 2001-03-22 JP JP2001572131A patent/JP2003528926A/ja active Pending
- 2001-03-22 EP EP01923695A patent/EP1265636A2/en not_active Withdrawn
- 2001-03-22 IL IL15183301A patent/IL151833A0/xx unknown
- 2001-03-22 KR KR1020027012287A patent/KR20020082487A/ko active Search and Examination
- 2001-03-22 US US09/814,572 patent/US20010039438A1/en not_active Abandoned
- 2001-03-22 RU RU2002127778/15A patent/RU2271222C2/ru not_active IP Right Cessation
- 2001-03-22 AU AU2001250401A patent/AU2001250401B2/en not_active Ceased
- 2001-03-22 KR KR1020077027215A patent/KR20070114856A/ko not_active Application Discontinuation
- 2001-03-22 CA CA002403612A patent/CA2403612A1/en not_active Abandoned
- 2001-03-22 EE EEP200200547A patent/EE200200547A/xx unknown
-
2002
- 2002-09-19 NO NO20024486A patent/NO20024486D0/no not_active Application Discontinuation
- 2002-09-23 ZA ZA200207638A patent/ZA200207638B/en unknown
-
2006
- 2006-07-11 US US11/484,473 patent/US20060263392A1/en not_active Abandoned
-
2007
- 2007-10-18 US US11/975,325 patent/US8158669B2/en not_active Expired - Fee Related
-
2012
- 2012-04-16 US US13/448,242 patent/US8862224B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6297228B1 (en) * | 1991-11-22 | 2001-10-02 | Alcon Manufacturing, Ltd. | Use of angiostatic steroids in photodynamic therapy |
US5770619A (en) * | 1992-11-20 | 1998-06-23 | University Of British Columbia | Method of activating photosensitive agents |
US6117862A (en) * | 1998-10-09 | 2000-09-12 | Qlt, Inc. | Model and method for angiogenesis inhibition |
US6214819B1 (en) * | 1998-11-23 | 2001-04-10 | Novartis Ag | Method for treating ocular neovascular diseases |
US6271233B1 (en) * | 1999-08-10 | 2001-08-07 | Ciba Vision Corporation | Method for treating ocular neovascular diseases |
US20020040015A1 (en) * | 2000-02-10 | 2002-04-04 | Miller Joan W. | Methods and compositions for treating conditions of the eye |
US20030175282A1 (en) * | 2000-02-10 | 2003-09-18 | Miller Joan W. | Methods and compositions for treating conditions of the eye |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
US20040122491A1 (en) * | 2001-02-06 | 2004-06-24 | Strong H. Andrew | Reduced fluence rate PDT |
US7753943B2 (en) * | 2001-02-06 | 2010-07-13 | Qlt Inc. | Reduced fluence rate PDT |
US20030171320A1 (en) * | 2001-11-09 | 2003-09-11 | Guyer David R. | Methods for treating ocular neovascular diseases |
US20070027101A1 (en) * | 2001-11-09 | 2007-02-01 | Guyer David R | Methods for treating ocular neovascular diseases |
US20040243198A1 (en) * | 2002-10-03 | 2004-12-02 | Light Sciences Corporation | System and method for excitation of photoreactive compounds in eye tissue |
US7288106B2 (en) | 2002-10-03 | 2007-10-30 | Light Sciences Oncology, Inc. | System and method for excitation of photoreactive compounds in eye tissue |
US8507431B2 (en) | 2003-08-07 | 2013-08-13 | Healor Ltd. | Methods for accelerating wound healing by administration of a preadipocyte modulator or an adipocyte modulator |
US20050043786A1 (en) * | 2003-08-18 | 2005-02-24 | Medtronic Ave, Inc. | Methods and apparatus for treatment of aneurysmal tissue |
US20050244500A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
US8367606B2 (en) | 2005-08-29 | 2013-02-05 | Healor Ltd. | Method and compositions for prevention and treatment of diabetic and aged skin |
US20100310542A1 (en) * | 2007-07-30 | 2010-12-09 | Healor Ltd. | Pharmaceutical Compositions for treating wouds and related methods |
Also Published As
Publication number | Publication date |
---|---|
CN1420788A (zh) | 2003-05-28 |
UA75350C2 (en) | 2006-04-17 |
AU5040101A (en) | 2001-10-15 |
WO2001074389A2 (en) | 2001-10-11 |
EP1265636A2 (en) | 2002-12-18 |
PL359027A1 (en) | 2004-08-23 |
AR032151A1 (es) | 2003-10-29 |
CA2403612A1 (en) | 2001-10-11 |
US8158669B2 (en) | 2012-04-17 |
HUP0300347A3 (en) | 2005-03-29 |
CZ20023174A3 (cs) | 2003-01-15 |
JP2003528926A (ja) | 2003-09-30 |
NO20024486L (no) | 2002-09-19 |
KR20070114856A (ko) | 2007-12-04 |
NO20024486D0 (no) | 2002-09-19 |
US20080096865A1 (en) | 2008-04-24 |
HUP0300347A2 (hu) | 2003-06-28 |
RU2271222C2 (ru) | 2006-03-10 |
CN100398153C (zh) | 2008-07-02 |
AU2001250401B2 (en) | 2005-08-11 |
EE200200547A (et) | 2004-02-16 |
MXPA02009351A (es) | 2003-02-12 |
US8862224B2 (en) | 2014-10-14 |
ZA200207638B (en) | 2003-10-16 |
NZ521360A (en) | 2004-07-30 |
US20120203162A1 (en) | 2012-08-09 |
IL151833A0 (en) | 2003-04-10 |
WO2001074389A3 (en) | 2002-07-11 |
KR20020082487A (ko) | 2002-10-31 |
BR0109499A (pt) | 2002-12-10 |
US20060263392A1 (en) | 2006-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8158669B2 (en) | Method for treating neovascularization | |
US6548542B1 (en) | Vision through photodynamic therapy of the eye | |
AU2001250401A1 (en) | Improved treatment of neovascularization | |
JP2003528926A5 (no) | ||
US20040220167A1 (en) | Methods of treating neuralgic pain | |
EP1570859A2 (en) | Improved treatment of neovascularization | |
AU705100C (en) | Improved vision through photodynamic therapy of the eye | |
JP2012092145A (ja) | 眼の光力学的治療による視力改善用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BRAZZELL, ROMULUS KIMBRO;REEL/FRAME:025141/0023 Effective date: 20010514 |